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Abstract: Oral cancer refers to all malignancies that arise in the oral cavity, lips and pharynx, with 90% of all oral cancers 
being oral squamous cell carcinoma. Despite the recent treatment advances, oral cancer is reported as having one of the 
highest mortality ratios amongst other malignancies and this can much be attributed to the late diagnosis of the disease. 
Saliva has long been tested as a valuable tool for drug monitoring and the diagnosis systemic diseases among which oral 
cancer. The new emerging technologies in molecular biology have enabled the discovery of new molecular markers 
(DNA, RNA and protein markers) for oral cancer diagnosis and surveillance which are discussed in the current review. 
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INTRODUCTION 
Oral cancer refers to all malignancies arising from
  the 
lips, the oral cavity, and pharynx [1] and it affects more than 
481,000 new patients worldwide. It is the sixth most com-
mon cancer in the USA [2]. The 90% of oral cancers are oral 
squamous cell carcinoma. This cancer, when found early, has 
an 80 to 90% survival rate. Despite this fact and the great 
treatment advances, the World Health Organization has re-
ported oral cancer as having one of the highest mortality 
ratios amongst other malignancies with a death rate at five 
years from diagnosis at 45% [3]. This high morbidity rate 
can definitely be attributed to the late diagnosis of the dis-
ease [4]. At the moment, a lack in national screening pro-
grams together with a lack of definitive and satisfactory bio-
logical markers [5-7] for early oral cancer detection has re-
sulted in late stage diagnosis of oral cancer [8]. An increas-
ing number of systemic diseases and conditions, amongst 
them oral cancer, have been shown to be reflected diagnosti-
cally in saliva. Moreover, using saliva as a diagnostic fluid 
meets the demands for inexpensive, noninvasive, and acces-
sible diagnostic methodology. 
Attempts on Early Oral Cancer Detection  
 The most reliable method for the diagnosis of oral can-
cer is a tissue biopsy followed by a histopathological evalua-
tion of the tissue specimen [9, 10]. This however takes as 
granted that a usually asymptomatic lesion will be detected 
by the patient who will be alerted and will then soon visit a 
dentist’s or other practitioner’s office [11]. Because oral can-
cers usually lack early signs, there have been in the past sev-
eral attempts towards the direction of early oral cancer detec-
tion and attention has been drawn to cancer screening pro-
grams [12, 13]. Most oral cancer screening programs include 
the simple visual inspection [9, 14], whereas others attempt  
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the use of toluidine blue [15, 16], brush biopsy (exfoliative 
cytology) [17, 18], chemiluminesce [19, 20] and fluores-
cence imaging [21]. The last three screening methods in fact 
deal with the diagnosis of lesions that have already been de-
tected by the patient, dentist or other clinician but a defini-
tive diagnosis can only be made by a tissue biopsy.  
However, according to Kujan et al. [22, 23], “there is not 
enough evidence to decide whether screening by visual in-
spection reduces the death rate for oral cancer and also no 
robust evidence exists to suggest that other methods of 
screening, toluidine, fluorescence imaging or brush biopsy 
are either beneficial or harmful”.  
Cancer Related Genetic Alterations Identified in Bodily
 
Fluids  
In the development of neoplastic disease, progressive
 
genotypic and phenotypic alterations such as the activation 
of protoncogenes and ongogenes and inactivation of tumor 
suppressor genes -associated with tumorigenesis- are de-
tected in the affected cells, establishing the model of multis-
tep tumorigenesis [24]. It has been shown that identical mu-
tations can be identified in bodily fluids draining a tumor [7], 
but, also lately in bodily fluids secreted away from the initial 
point where a solid tumor is developing [25, 26]. Nucleic 
acids and proteins related to cancer cells have been detected 
in plasma/serum [27-29], urine [30, 31], saliva [32, 33], 
bronchoalveolar lavage fluid [27], cerebrospinal fluid [34] 
and other bodily fluids. These nucleic acids and proteins 
have been used as molecular markers for the early diagnosis 
of the disease [33, 35, 36], recurrence markers [37] survival 
and metastasis predictors [38, 39] and decide the therapeutic 
approach [40, 41]. 
Saliva as a Perfect Diagnostic Medium 
Whole saliva is the product of the secretions of the 3 ma-
jor salivary glands (parotid, submandibular, sublingual) and 
the numerous minor salivary glands mixed with crevicular 
fluid, bronchial and nasal secretions, blood constituents from 
wounds or bleeding gum, bacteria, viruses, fungi, exfoliated Salivary Markers  The Open Dentistry Journal, 2010, Volume 4    173 
epithelial cells and food debris [42, 43]. Saliva has been long 
proposed and used as a diagnostic medium [44-46] because 
it is easily accessible and its collection is non-invasive, not 
time-consuming, inexpensive, requires minimal training and 
can be used for the mass screening of large population sam-
ples [46, 47]. 
Whole saliva can be collected with or without stimula-
tion. Stimulation can be performed with masticatory move-
ments or by gustatory stimulation (citric acid) [48]. Stimu-
lated saliva however, it can be collected in larger quantities, 
is a little bit altered in content [49]. Unstimulated saliva can 
be collected by merely spitting in a test tube or by leaving 
saliva drool from the lower lip [50] and it is more often used 
for the diagnosis or follow up of systemic diseases. 
Saliva has long been used for the monitoring of drug 
abuse (drugs and addictive substances) such as cocaine, her-
oin, amphetamine, barbiturates [51] etc. Moreover salivary 
testing has largely performed for the diagnosis of HIV-
infection [52, 53]. Analysis of salivary parameters such as 
salivary flow rate, pH, buffer capacity, lactobacillus, and 
yeast content, presence of IgG, IgM and anti-La autoantibod-
ies and raised protein levels such as that of lactoferrin and 
cystatin C as has been proposed for the diagnosis of 
Sjogren’s syndrome [54, 55]. Concerning cancer diagnostics 
and follow up altered levels of certain mRNA molecules [33, 
56] have been detected in saliva in oral cancer patients and 
of certain proteins in several cancers [25, 26, 57]. 
Speculations about Possible Mechanisms that Lead to the 
Presence of Genotypic and Phenotypic Markers in the 
Saliva 
Cell-free nucleic acids and proteins in saliva may derive 
from serum or can be locally produced [58].  
Serum derived nucleic acids and proteins in the saliva 
may be part of the normal salivary secretion (by the acinar 
cells) [59] or come there either via intracellular routes such 
as active transport or passive diffusion [60] from the serum 
to saliva across cell membranes or extracellular routes such 
as ultrafiltration through tight junctions [61] or as constitu-
ents of the outflowing crevicular fluid.  
Cell free nucleic acids and proteins in saliva however can 
be locally produced by cell necrosis, lysis or apoptosis and 
trauma and may even be actively released by normal epithe-
lial or cancerous cells. Cell necrosis is a possible mechanism 
leading to the release of cell free nucleic acids and proteins 
in the saliva and this idea is also supported by the large 
amount of DNA in the plasma of patients with cancers in an 
advanced stage. Moreover, mounting evidence exists con-
cerning the presence of cell-free nucleic acids and proteins in 
apoptotic bodies [62] which also protect these molecules 
from degradation [63]. The active release of these molecules 
in exosomes or microvesicles is another strong possibility 
[64]. Exosomes or microvesicles are released by living cells. 
They are membrane vesicles, 40–100-nm in diameter [65], 
originating from the endoplasmic reticulum and are released 
when fused with the cell membrane. They contain mRNA 
[66], miRNA [67] and proteins [68, 69] and are thought to 
play a role in the cell-free intercellular communication [69-
71], Table 1.  
Salivary Markers for Oral Cancer Detection 
Molecular markers for the diagnosis of OSCC can be 
quested in 3 levels; (I) changes in the cellular DNA, which 
result in (II) altered mRNA transcripts, leading to (III) al-
tered protein levels (intracellularly, on the cell surface or 
extracellularly). All these markers are summarized in Table 
2. 
Changes in the Cellular DNA  
Typical changes in the host DNA of dysplastic or cancer 
cells include point mutations, deletions, translocations, am-
plifications and methylations, cyclin D1, epidermal growth 
factor receptor (EGFR), microsatellite instability and HPV 
presence.  
Allelic loss on chromosomes 9p has been observed in 
OSCC [72]. Mitochondrial DNA mutations have also been 
useful targets to detect exfoliated OSCC cells in saliva. They 
have been identified in 46% of head and neck cancers. The 
same mitochondrial DNA mutations were detected in 67% of 
saliva samples from OSCC patients by direct sequencing 
alone [73]. p53 gene mutations are also present in approxi-
mately one-half of head and neck cancers [74, 75]. Using 
plaque hybridization, Boyle et al. [75] identified tumor spe-
cific p53 mutations in 71% saliva samples from patients with 
head and neck cancer. 
Table 1.  Mechanisms that Lead to the Presence of Genotypic and Phenotypic Markers in the Saliva 
Normal salivary secretion 
Passive diffusion 
Active transport 
Ultrafiltration through tight junctions 
Serum derived 
Outflow of crevicular fluid 
Cell necrosis, lysis 
Apoptosis 
Trauma 
Cell-free nucleic acids & proteins in saliva 
Locally produced 
Active release 
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Promoter hypermethylation of several genes has been re-
ported in head and neck cancer. Rosas et al. identified aber-
rant methylation of at least one of three genes (p16, MGMT, 
or DAP-K) in OSCC. Abnormal promoter hypermethylation 
was also detected in the matched saliva sample in 65% of 
OSCC patients [76]. 
Cyclin D1 gene amplification has been found to be asso-
ciated with poor prognosis in OSCC [77]. In another study 
Ki67 markers were increased, while 8-oxoguanine DNA 
glycosylase, phosphorylated-Src and mammary serine prote-
ase inhibitor (Maspin) were found decreased in the saliva of 
patients with OSCC [78]. 
Microsatellite alterations of DNA were also observed in 
the saliva of patients with small cell lung cancer [79]. In the 
same study it was further demonstrated that 93% of the pa-
tients with microsatellite instability in tumor DNA also had 
similar microsatellite alterations in the corresponding plasma 
DNA. 
The presence of HPV (human papilloma virus) and Ep-
stein Barr virus genomic sequences have been identified as 
possible DNA molecular markers in detecting OSCC and 
tumor progression [80, 81].  
Altered mRNA Transcripts 
RNA for years was thought to quickly degrade in saliva 
due to the various RNAses that saliva contains [82]. Despite 
the opposite reports [83], cell-free RNA molecules however, 
seem to exist in saliva both intact but also fragmented [84]. 
An intriguing question that remains to be answered is the 
mechanism by which mRNA in saliva is protected by degra-
dation. A speculation is that salivary mRNA is contained in 
apoptotic bodies [63, 64] or actively released in exosomes or 
microvesicles [66, 68,70]. Lately microRNAs, small RNA 
molecules, 18-24 molecules in length, that seem to regulate 
transcription were also discovered existing in saliva [85-87].  
mRNA detection in saliva has been extensively reported 
enabling body fluid identification in Forensic Medicine [88, 
89]. Moreover mRNA markers in the saliva have been pro-
posed for the diagnosis of primary Sjögren’s syndrome [90] 
and for the identification of sleep drive both in flies but also 
in humans [91]. 
Various mRNA molecules were found up-regulated in 
the saliva of patients suffering from OSCC by the team of Li 
et al. [33]. Seven mRNA molecules: transcripts of: 1. IL8 
(interleukin 8) playing a role in angiogenesis; replication; 
calcium-mediated signaling pathway; cell adhesion; chemo-
Table 2.  Molecular Markers for the Diagnosis of Oral Squamous Cell Carcinoma 
Changes in the cellular DNA  Altered mRNA transcripts  Altered protein markers 
Allelic loss on chromosomes 9p  Presence of IL8  Elevated levels of defensin-1 
Mitochondrial DNA mutations  Presence of IL1B  Elevated CD44 
p53 gene mutations  DUSP1 (dual specificity phosphatase 1)  Elevated IL-6 andIL-8 
Promoter hypermethylation of genes (p16, 
MGMT, or DAP-K) 
H3F3A (H3 histone, family 3A)  Inhibitors of apoptosis (IAP) 
Cyclin D1 gene amplification  OAZ1 (ornithine decarboxylase antizyme 1)  Squamous cell carcinoma associated anti-
gen (SCC-Ag) 
Increase of Ki67 markers  S100P (S100 calcium binding protein P)  Carcino- embryonic antigen (CEA) 
Microsatellite alterations of DNA SAT (spermidine/spermine N1-acetyltransferase)  Carcino-antigen (CA19-9) 
Presence of HPV    CA128 
    Serum tumor marker (CA125) 
    Intermediate filament protein (Cyfra 21-1) 
    Tissue polypeptide specific antigen (TPS) 
    Reactive nitrogen species (RNS) 
    8-OHdG DNA damage marker 
    Lactate dehydrogenase (LDH) 
   Immunoglobulin  (IgG) 
   s-IgA 
    Insulin growth factor (IGF) 
    Metalloproteinases MMP-2 and MMP-11 
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taxis; cell cycle arrest; immune response, 2. IL1B (interleu-
kin 1) which takes part in signal transduction; proliferation; 
inflammation and apoptosis 3. DUSP1 (dual specificity 
phosphatase 1) with a role in protein modification; signal 
transduction and oxidative stress, 4. H3F3A (H3 histone, 
family 3A) having a DNA binding activity, 5. OAZ1 (or-
nithine decarboxylase antizyme 1) taking part in polyamine 
biosynthesis 6. S100P (S100 calcium binding protein P) with 
a role in protein binding and calcium ion binding, and 7. 
SAT  (spermidine/spermine N1-acetyltransferase) which 
takes part in enzyme and transferase activity- were found 
significantly elevated in OSCC patients rather than in 
healthy controls [56]. 
Altered Protein Markers  
Several salivary protein markers for OSCC have been in-
vestigated in various studies and have shown relatively mod-
erate sensitivity and specificity values relative to prognosis 
prediction. 
For example, defensins are peptides which possess an-
timicrobial and cytotoxic properties. They are found in the 
azurophil granules of polymorphonuclear leukocytes [92, 
93]. Elevated levels of salivary defensin-1 were found to be 
indicative for the presence of OSCC, since higher concentra-
tions of salivary defensin-1 were detected in patients with 
OSCC compared with healthy controls [94].  
In another study soluble CD44 [95] was found to be ele-
vated in the majority of patients with OSCC and distin-
guished cancer from benign disease with high specificity. 
Whereas the solCD44 test lacks sensitivity by itself, methy-
lation status of the CD44 gene seems to complement the 
solCD44 test and provides very high sensitivity and specific-
ity for the detection of OSCC. 
St John et al. [32] investigated whether IL-6 and/or IL-8 
could serve as informative biomarkers for OSCC in saliva. 
Interleukin 8 was detected at higher concentrations in saliva, 
while IL-6 was detected at higher concentrations in serum of 
patients with OSCC. Thus, they concluded that IL-8 in saliva 
and IL-6 in serum hold promise as biomarkers for OSCC.  
A group of leading researchers [33, 56, 96-99] using new 
and sophisticated approaches, such as, Luminex Multianalyte 
Profiling (xMAP) technology, shotgun proteomics, capillary 
reversed-phase liquid chromatography with quadruple time-
offlight mass spectrometry and matrix-assisted laser desorp-
tion/ionization–mass spectrometry (MALDI–MS), has con-
tributed significantly in recent years to the research in saliva 
for cancer diagnosis. Their studies have shown that saliva 
contains proteins that may serve as biomarkers for OSCC, 
since 46 peptides/proteins were found at significantly differ-
ent levels between the OSCC and control groups. For exam-
ple Arellano-Garcia et al. [100] using Luminex xMAP tech-
nology showed that both IL-8 and IL-1 were expressed at 
significantly higher levels in OSCC subjects. 
Other salivary biomarkers which have been shown to be 
significantly altered in OSCC patients as compared with 
healthy controls are inhibitors of apoptosis (IAP) [101], 
squamous cell carcinoma associated antigen (SCC-Ag) [102-
104], carcino- embryonic antigen (CEA) [102, 103], carcino-
antigen (CA19-9) [102, 104], CA128 [102, 104], serum tu-
mor marker (CA125) [105], intermediate filament protein 
(Cyfra 21-1) [106-108], tissue polypeptide specific antigen 
(TPS) [108, 109], reactive nitrogen species (RNS) and 8-
OHdG DNA damage marker [106], lactate dehydrogenase 
(LDH) and immunoglobulin (IgG) [107], s-IgA [110], insu-
lin growth factor (IGF) [110], metalloproteinases MMP-2 
and MMP-11 [110]. 
CONCLUSIONS  
For years saliva is tested as a diagnostic fluid and com-
pared to blood (serum or plasma) in parameters such as sen-
sitivity, specificity and applicability of the method, cost and 
duration of the procedure, patient compliance [111] etc. Due 
to the recent advances and emerging technologies in molecu-
lar biology new molecular markers (DNA, RNA and protein 
markers) have been discovered existing in the saliva in meas-
urable quantities [112]. OSCC can be diagnosed with high 
sensitivity and specificity by merely testing saliva samples 
from the subjects. This does not of course undermine the 
value of screening tests by visual examination neither the 
importance of the tissue biopsy. 
Despite the scepticism in the scientific community and 
the conservatism of the patients, saliva seems to emerge as a 
valuable tool in cancer diagnostics and mass population 
screening. In our opinion much attention must be given to 
the saliva collecting method. An attempt to integrate the si-
multaneous testing of different salivary molecular markers in 
order to raise the possibility of an accurate diagnosis by sim-
ply using micro- and nano-electrical-mechanical systems 
biosensors is on the way raising much hope in its future ap-
plications [113]. 
Finally, since the present methods are not ready for im-
mediate clinical use as diagnostic tools, much work is neces-
sary and it can be envisaged that simple, fast, portable and 
cost-effective clinical diagnostic systems could be available 
in the near future. 
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